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Background: Quantum dots (QDs) have been used as novel fluorescent nanoprobes for various bioapplications.
The degradation of QDs, and consequent release of free cadmium ions, have been suggested to be the causes of
their overall toxicity. However, in contrast to sufficient investigations regarding the biological fate of QDs, a paucity
of studies have reported their chemical fate in vivo. Therefore, the overall aim of our study was to understand the
chemical fate of QDs in vivo and explore analytical techniques or methods that could be used to define the
chemical fate of QDs in vivo.
Methods: Male ICR mice were administered a single intravenous dose (0.2 μmol/kg) of aqueous synthesized CdTe/
ZnS aqQDs. Inductively coupled plasma-mass spectrometry (ICP-MS) was used to simultaneously measure the
concentrations of cadmium (Cd) and tellurium (Te) in the blood and tissues over the course of a 28 day period. We
compared the blood kinetic parameters and biodistributions of Cd and Te, and used the molar ratio of Cd:Te as a
marker for QDs degradation.
Results: Cd and Te display different blood kinetics and biodistribution profiles. The Cd:Te ratio in the blood did not
vary significantly within the first hour compared with intact CdTe/ZnS aqQDs. The Cd:Te ratio decreased gradually
over time from the 6 h time point on. Cd accumulated in the liver, kidneys, and spleen. Te was distributed primarily
to the kidneys. Sharp time-dependent increases in the Cd:Te ratio were found in liver tissues.
Conclusions: QDs can undergo degradation in vivo. In vitro, QDs are chemically stable and do not elicit the same
biological responses or consequences as they do in vivo. Our methods might provide valuable information
regarding the degradation of QDs in vivo and may enable the design and development of QDs for biological and
biomedical applications.
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Quantum dots (QDs) are recognized to be novel, high-
performance biological probes that are at the forefront of
nano-biotechnology research because they possess many
attractive optical properties, including a high photo-
luminescent quantum yield (PLQY), a broad absorption
spectrum coupled with narrow emission, and strong
photostability [1-3]. However, cadmium (Cd), which is
capable of inducing known toxicities in humans (including
hepatic, renal, neurologic, and/or genetic toxicities) [4,5],
is the most abundant component of QDs. The degradation
of QDs, and consequent release of free cadmium ions
(Cd2+), have been suggested to be the causes of their
overall toxicity. Therefore, it is critically important to sys-
tematically evaluate the chemical fate of QDs given their
widespread applications in biology [6].
Two strategies were used in order to synthesize QDs:
organic synthesis (orQDs) and aqueous synthesis (aqQDs).
Aqueous synthetic strategies are simpler, cheaper, and
more environmentally friendly than organic synthesis
methods. More importantly, aqQDs are naturally water-
dispersed and do not have large amounts of hydrophilic li-
gands covering their surfaces. Therefore, aqQDs possess a
much smaller hydrodynamic diameter than orQDs. Highly
luminescent aqQDs have been thoroughly developed and
used in various bioapplications, including bioimaging and
protein chips [7-9]. Cadmium-telluride (CdTe) QDs
surrounded by a thin shell or cap of zinc sulfides (ZnS)
(CdTe/ZnS aqQDs) are one of the most successful exam-
ples. As with all QDs, the CdTe core of the CdTe/ZnS
aqQDs is composed of covalently bound Cd and tellurium
(Te) that are held at a constant molar ratio (Cd:Te). As a
result of the stability of the covalently bound CdTe core
and the apparent ‘inertness’ of the CdTe complex (as op-
posed to the reactive nature of Cd2+), this bound Cd com-
plex has no valence charge and, therefore, no biological
reactivity. The exposed CdTe/ZnS aqQDs are therefore
believed by many to be biologically safe and non-toxic.
However, if the CdTe core is degraded, the release of Cd2+
and telluride ions (Te2-) from the CdTe core will increase
the risk of target organ toxicities [4,5,10].
To better understand and predict the efficacy and side
effects of QDs in vivo, four key questions need to be
addressed: What is the pharmacokinetic profile of QDs?
Where are these nanocrystals deposited (tissue dispo-
sition of QDs) within the body? How long do the depo-
sited QDs remain in the tissues or organs? What happens
to the QDs particles when they are in a biological system?
Work conducted by Fischer’s group resulted in the first
quantitative report on the in vivo biodistribution of QDs
in 2006 [11]. Several subsequent in vivo pharmacokinetic
studies of QDs have been completed [12-14]. The results
of these studies suggest several key points: (i) administered
QDs have a rather wide range (from 48 min to 20 h) ofhalf-lives (t1/2) in the bloodstream; (ii) QDs do not remain
in the circulation and tend to accumulate in organs and
tissues; (iii) QDs that are injected intravenously are more
likely to accumulate in the liver, spleen, and kidneys; and
(iv) the in vivo behavior of QDs is greatly dependent on
their hydrodynamic diameters. QDs with smaller hydro-
dynamic diameters are more rapidly and efficiently elimi-
nated via renal clearance in mice than those with large
hydrodynamic diameters (>15 nm). In contrast to the suffi-
cient investigations outlined above, there have been rela-
tively few studies addressing the chemical fate of QDs
in vivo.
In our previous studies regarding the pharmacokine-
tics and tissue distribution of CdTe aqQDs, we found
that Cd and Te display different plasma kinetics and dis-
tribution patterns [15]. The different plasma kinetics and
distribution patterns of Cd and Te imply that CdTe
aqQDs may undergo degradation in vivo. To further ex-
plore the degradation of QDs, we investigated the
in vivo properties of CdTe/ZnS aqQDs, including blood
pharmacokinetics and the long-term biodistribution of
Cd and Te. Moreover, based on the atomic weights of
Cd and Te, the Cd:Te ratios in the blood and tissues
over time were calculated and were used to reflect the
general stability and conditions of CdTe/ZnS aqQDs in
biological systems. As compared with the initial and
normal Cd:Te ratio in CdTe/ZnS aqQDs, steady or
unchanged Cd:Te ratios in the blood and tissues over
time indicate that the CdTe/ZnS aqQD complexes have
remained intact. In contrast, alterations in the Cd:Te ra-
tio signify disintegration of the complex. In addition, the
chemical fate of CdTe/ZnS aqQDs in vitro and in vivo
were examined as well. Based on the blood kinetic pa-
rameters and biodistributions of Cd and Te, as well as
alterations in the Cd:Te ratio, we believe that we can as-
sess the chemical fate of CdTe/ZnS aqQDs in biological
systems. Although QDs have different core compositions
(for example, gallium-, copper-, lead-, and arsenide-
based QDs), different QDs may behave similarly in bio-
logical systems. The information generated from our
studies may contribute to the general understanding of
QDs and the evaluation of the biological risks associated
with their use.
Results
Characteristics of CdTe/ZnS aqQDs
For atomic force microscopy (AFM) measurements, only
the Z-dimension was used to determine the size in order
to avoid probe-related artifacts. These measurements
yielded a mean size of 19.3 ± 2.2 nm. The shape of the
CdTe/ZnS aqQDs was approximately spherical (Figure 1A).
The emission spectra of the aqQDs are presented in
Figure 1B. The maximal emission was 652 nm (at λex =
350 nm). The concentration of the CdTe/ZnS aqQDs stock
Figure 1 Characteristics of CdTe/ZnS aqQDs: (A) AFM image, (B) absorption and emission spectra. The average size was 19.3 ± 2.2 nm in
diameter. The maximal emission was observed at approximately 652 nm following excitation at 350 nm.
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mass of Cd). The Cd:Te ratio was 3:1, and the molar ratio
of zinc (Zn) to Cd (Zn:Cd) was 1:1.
Stability of CdTe/ZnS aqQDs in vitro
The stability data for the CdTe/ZnS aqQDs in vitro are
shown in Figure 2 and Table 1. Figure 2 illustrates that
in the first 20 days, the PLQYs of CdTe/ZnS aqQDs in
situ were not significantly different (ranging from 70.3
to 72.3%). The PLQYs gradually decreased over the next
20 days, and the values had dropped to 43.8% of their
original values 80 days later. Table 1 shows that the
maximal emission (652 nm) of CdTe/ZnS aqQDs was
not altered by dialyses lasting up to 3 d in pH 7.4 buff-
ered solutions, but dialysis rapidly reduced the relative
fluorescence intensity after 6 h (from 271.0 to 144.1).
After 3 d, only 55.2 remained. In the filtrate, theFigure 2 PLQY transformation of CdTe/ZnS aqQDs in situ
(pH 8.3) for periods up to 80 days.concentrations of Cd, Te, and Zn gradually increased
with time, but Cd:Te ratios did not vary significantly
(the molar ratio of Cd and Te in CdTe/ZnS aqQDs used
in this study was 3:1). Zn:Cd ratios were not significantly
different (the molar ratio of Zn and Cd in CdTe/ZnS
aqQDs used in this study was 1:1) in the first 6 h, but at
the 24 h, 2 and 3 d time-points, the ratios had become
slightly elevated (from 1.13:1 to 1.26:1).Comparative Cd and Te blood kinetics
We did not observe significant changes in body or organ
weights in the mice after tail vein injections of CdTe/
ZnS aqQDs (Additional file 1: Table S1). Additionally,
no symptoms of illness were observed in the mice at the
dose of aqQDs administered during the experimental
period, and all of the animals survived until the end of
the experimental period.
The Cd and Te concentrations in the blood are
presented in Table 2. Table 2 shows that blood Cd con-
centrations were much higher than Te concentrations
for the first day after injection. At 3 d post-injection, the
Cd concentrations were below the limit of detection and
were much lower than the Te concentrations. The Cd:
Te ratios did not vary significantly in the first hour. The
ratios were 3.01:1 (1 min), 2.95:1 (15 min), 2.95:1
(30 min) and 2.94:1 (1 h). All of the ratios were approxi-
mately 3:1, which corresponds to the Cd:Te ratio in the
CdTe/ZnS aqQDs used in this study. From the 6 h time
point on, the Cd:Te ratios decreased gradually over time
from 2.48:1 to 1.87:1. The main kinetic parameters shown
in Table 3 were fit using a two-compartment model with a
weighting factor of 1/c2, in which Cd and Te varied. Cd
exhibited a significantly greater area under the blood
concentration-time profiles (AUC) (2.16 ± 0.07 μg · h/ml
vs. 0.99 ± 0.13 μg · h/ml, p < 0.01), clearance (CL) (10.40 ±
0.48 ml/h/kg vs. 8.99 ± 1.53 ml/h/kg, p < 0.05) and a
rapider elimination half-life (t1/2β) (12.41 ± 0.26 h vs.
14.40 ± 1.33 h, p < 0.05) than Te.





Metal concentrations in filtrate (ng/ml) Molar ratios of metals in filtrate
Cd Te Zn Cd:Te Zn:Cd
Initial time 652 271.0 ± 6.5 ND ND ND ND ND
15 min 652 270.5 ± 5.8 2.08 ± 0.12 0.81 ± 0.01 1.30 ± 0.01 2.92:1 1.08:1
30 min 652 270.6 ± 7.9 7.20 ± 0.21 2.90 ± 0.02 4.08 ± 0.05 2.82:1 0.98:1
1 h 652 270.0 ± 9.0 7.72 ± 0.48 2.88 ± 0.30 4.82 ± 0.12 3.05:1 1.08:1
6 h 652 144.1 ± 12.8 8.52 ± 0.95 3.36 ± 0.45 5.02 ± 0.38 2.88:1 1.02:1
24 h 652 104.2 ± 11.1 11.90 ± 1.06 4.91 ± 0.36 7.77 ± 1.01 2.75:1 1.13:1
2 d 652 86.2 ± 10.9 12.87 ± 1.24 5.04 ± 0.44 9.08 ± 0.91 2.90:1 1.22:1
3 d 652 55.2 ± 2.6 14.42 ± 1.80 5.63 ± 0.61 10.50 ± 1.08 2.91:1 1.26:1
ND not detectable. All data are represented as the mean ± SD, n = 3.
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Figure 3A illustrates the tissue distribution of Cd in ICR
mice exposed to CdTe/ZnS aqQDs. After intravenous
injection, Cd mainly accumulated in the liver and kid-
neys. Accumulation was also observed in the spleen,
lungs and heart. Cd was rarely distributed in the brain.
The peak concentration and peak time of Cd in each
organ after administration differed. They were: 22.1 ±
4.74 ng/g at 24 h in the heart, 102.82 ± 18.93 ng/g at 3 d
in the liver, 42.04 ± 11.22 ng/g at 7 d in the spleen,
18.03 ± 1.27 ng/g at 24 h in the lungs and 66.75 ±
12.75 ng/g at 7 d in the kidneys. By plotting the tissue
concentrations versus time, we found that Cd elimin-
ation from the liver, kidneys and spleen was significantly
slower than Cd elimination from the lungs and heart.
Moreover, there were obvious increases in the Cd
concentrations in the kidneys at 28 d. At 28 d post-
exposure, 42.94, 14.69 and 42.60 ng/g remained in the
liver, spleen and kidneys.
The distribution of Te in different tissues is shown in
Figure 3B. The kidneys appeared to be the major target
organs for Te deposition. Te was also deposited in the
heart, liver, spleen and lungs. The brain contained only a
very small amount of Te. The peak concentration and
peak time of Te in each organ after administrationTable 2 Blood concentration-time curves of Cd and Te in
mice exposed to CdTe/ZnS aqQDs
Exposed time Cd (ng/ml) Te (ng/ml) Cd:Te
1 min 195.23 ± 1.78 73.60 ± 2.40 3.01:1
15 min 142.40 ± 3.40 54.80 ± 0.57 2.95:1
30 min 123.70 ± 2.68 47.60 ± 3.32 2.95:1
1 h 108.80 ± 1.98 42.05 ± 1.13 2.94:1
6 h 91.00 ± 2.24 41.70 ± 3.11 2.48:1
12 h 66.23 ± 1.90 26.50 ± 1.27 2.30:1
24 h 24.33 ± 4.29 10.10 ± 4.25 1.87:1
3 d ND 7.10 ± 1.42 ND
ND not detectable. All data are represented as the mean ± SD, n = 6.differed. They were: 10.55 ± 0.58 ng/g at 24 h in the
heart, 9.63 ± 0.56 ng/g at 3 d in the liver, 9.10 ± 0.87 ng/g
at 3 d in the spleen, 6.74 ± 1.07 ng/g at 24 h in the lungs
and 20.10 ± 2.09 ng/g at 24 h in the kidneys. The peak
times of Te in the heart, liver and lungs after administra-
tion were similar to Cd in these organs. In the spleen, Te
concentrations increased during the first 3 d and reached
peak concentrations (9.10 ng/g). However, from 3 to 28 d,
the Te concentrations did not vary significantly (9.10–
8.13 ng/g), indicating that elimination had rarely occurred.
In the kidneys, the Te concentrations increased sharply
during the first day (from 6.53 to 20.10 ng/g), but elimi-
nation was significantly slower from 24 h (20.10 ng/g) to 7
d (19.02 ng/g). At 14 d post-exposure, the majority of Te
had been eliminated, with only 2.89 ng/g remaining.
Time-dependent changes in the Cd:Te ratios
The Cd:Te ratios in the tissues were calculated over time
and are shown in Table 4. At the 15 min time-point,
they were: 2.77:1 (heart), 3.02:1 (liver), 3.02:1 (spleen),
2.94:1 (lungs), 3.21:1 (kidneys), and 3.22:1 (brain). All of
the ratios were approximately 3:1, which corresponds to
the molar ratio of Cd and Te in the CdTe/ZnS aqQDs
used in this study. Furthermore, different trends in the
Cd:Te ratios in the organs were observed. The Cd:TeTable 3 Kinetic parameters of Cd and Te in mice exposed
to CdTe/ZnS aqQDs
Kinetic parameters Unit Cd Te
Vd ml/kg 110.48 ± 1.36 115.91 ± 2.44
AUC μg · h /ml 2.16 ± 0.07** 0.99 ± 0.13
CL ml/h/kg 10.40 ± 0.48* 8.99 ± 1.53
t1/2α h 0.14 ± 0.06 0.13 ± 0.03
t1/2β h 12.41 ± 0.26
* 14.40 ± 1.33
Vd, apparent volume of distribution, AUC, area under the blood concentration-
time profiles, CL, clearance t1/2α, distribution half-life, t1/2β, elimination half-life.
Kinetic parameters (AUC, CL and t1/2β) of Cd were significantly different
compared with those of Te in the blood, *p < 0.05, **p < 0.01.
All data are represented as the mean ± SD, n = 6.
Figure 3 Bio-distribution of Cd (A) and Te (B) in mice exposed to CdTe/ZnS aqQDs. ICR mice were injected via tail vein with CdTe/ZnS
aqQDs (0.2 μmol/kg). Serial sacrifices were carried out at 15 min, 1 h, 6 h, 24 h, 3 d, 7 d, 14 d, and 28 d after dosing. Several organs/tissues,
including heart, liver, spleen, lungs, kidneys, and brain were isolated to determine concentrations of Cd and Te with ICP-MS. The mean values of
the control were deducted as the baseline (Additional file 2: Table S2). All data are represented as the mean ± SD, n = 6.
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period of 7 days, but began to decrease gradually after
14 d. In the liver, the Cd:Te ratios increased sharply with
time from 1 h through 28 d. In the spleen and lungs, the
Cd:Te ratios did not change significantly over a period
of 3 d, increased at 7 d and decreased from 14 d on. In
the kidneys, the Cd:Te ratios decreased at 24 h and
increased gradually from 7 d on. These findings indicate
that the CdTe/ZnS aqQDs steadily disintegrated in vivo.
In addition, the degree of degradation of CdTe/ZnS
aqQDs differed in various organs.
Discussion
This study is an extension of our previous study, which
was aimed at understanding the chemical fate of QDs
in vivo. While there has been no lack of studies regarding
the fate and biological safety of QDs, many of these stud-
ies were conducted in vitro [16-21]. Because cultured cells
do not metabolize complex chemicals, in vitro cultures
can not replicate complicated in vivo systems. Therefore,
studies examining the actual chemical fate of QDs in in-
tact biological systems (animal studies) are needed. This
information is critical for the evaluation of the toxicity of
QDs and other nanoparticles.Table 4 Cd:Te radios in the tissues of mice exposed to
CdTe/ZnS aqQDs
Exposed time Heart Liver Spleen Lungs Kidneys Brain
15 min 2.77:1 3.02:1 3.02:1 2.94:1 3.21:1 3.22:1
1 h 3.34:1 4.60:1 3.19:1 2.76:1 2.14:1 3.35:1
6 h 3.03:1 5.86:1 2.88:1 2.91:1 2.41:1 2.81:1
24 h 2.39:1 7.73:1 2.88:1 3.04:1 1.35:1 2.59:1
3 d 3.14:1 12.12:1 2.82:1 2.59:1 1.87:1 2.35:1
7 d 2.93:1 16.85:1 5.72:1 4.31:1 3.98:1 1.37:1
14 d 0.41:1 21.42:1 4.38:1 1.18:1 4.66:1 0.87:1
28 d 0.39:1 29.05:1 1.90:1 0.31:1 16.56:1 1.02:1QDs exhibit narrow emission profiles and can emit
clear and bright colors based on their strong fluores-
cence intensities. A fluorescence spectrometer was used
to reveal some of the parameters (size and concentra-
tion) of QDs. When QDs degrade (loss of surface atoms
and decreases in the size of QDs), blue-shifts in the
excitation fluorescence spectra and decreases in the
quantum yield are observed [22]. However, using fluo-
rescence intensity to quantify QDs in blood and tissues
has been deemed to be problematic due to the high and
variable background fluorescence that result from native
blood and tissues. Moreover, the fluorescence of QDs is
susceptible to environmental factors. For example, the
PLQY has been demonstrated to change drastically as a
result of surface chemistry, rearrangement of surface li-
gands, photoenhanced oxidization, and solvent effects.
Any of these parameters can potentially cause large devi-
ations in fluorescence measurements [13]. Therefore,
using fluorescence intensity and peak wavelength in
order to determine the chemical fate of QDs in vivo was
deemed to be problematic. Inductively coupled plasma-
atomic emission spectrometer (ICP-AES) and induct-
ively coupled plasma-mass spectrometry (ICP-MS) are
highly sensitive methods that can be used to detect most
elements. For example, the detection limit for Cd can
approach 0.1 ng/ml using ICP-MS. Fischer et al. [11]
first tracked QDs via Cd measurements in the blood and
organs of rats using ICP-AES and presented a quantita-
tive report on the kinetic parameters and biodistribution
of QDs in the rat. Several subsequent biological fate
studies of QDs in vivo using ICP-AES and ICP-MS have
been reported [12-14]. However, the ICP-AES or ICP-
MS analytical techniques were unable to distinguish
whether Cd was bound within the QDs or had been re-
leased into the tissues. This distinction is important
because bound Cd has no valence charge and, thus, is
most likely much less biologically reactive or toxic than
highly charged free Cd2+.
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were incubated with whole blood, and samples were re-
trieved and centrifuged at various times in order to investi-
gate whether the QDs interacted with blood components.
The supernatant (plasma) was analyzed for QDs using
fluorescence spectroscopy and ICP-AES, whereas the pellet
was further analyzed using fluorescence microscopy. The
authors verified using optical microscopy that the QDs
exhibited minimal, nonspecific binding to the cellular
blood components of the rat (e.g., erythrocytes). Other
studies [13] mimicked the pHs of blood (pH 7.4) and the
renal tubules (pH 4.8) in order to investigate the stability of
CdSeS/SiO2 QDs that had been stored in a buffer for five
days. The results revealed that the maximal emission of
CdSeS/SiO2 QDs was not altered and that the fluorescence
intensity was stable after five days of incubation in either
pH 7.4 or pH 4.8 buffer solutions. Because the concentra-
tion of Cd in the supernatant of the experimental solution
in both pH environments did not significantly differ from
that in the phosphate buffered saline (PBS) blank, the au-
thors concluded that Cd concentrations could be used to
estimate the concentration of QDs in their in vivo studies.
However, in vivo toxicity (or perceived toxicity) of the high
surface area-to-volume ratio of QDs, which provides a
large available surface for enzymatic degradation and the
release of metallic ions, has been previously reported.
Fitzpatrick et al. [23] studied the persistence of CdSe/ZnS
QDs that had been coated with mPEG 5000 (emitting at
655 nm) in mice. They noted that immediately after injec-
tion into the tail vein, emissions related to the QDs were
observed in the circulatory system and various organs, in-
cluding the liver, spleen, lymph and bone marrow. The
fluorescence signals observed were found to have been
blue-shifted from the initial emission wavelengths, due to
the loss of one monolayer of the nanoparticle. Within five
days, the emission observed in the liver had faded, indicat-
ing that extreme degradation of the QDs had occurred
with concomitant release of Cd. Pi et al. [24] labeled mouse
embryonic stem cells (ESCs) with QDs and monitored
QD-labeling using fluorescence microscopy for 72 h. A
rapid loss of QD-labeling in ESCs was observed within
48 h. Transmission electron microscopy (TEM) analysis
showed a dramatic decrease in QDs in the vesicles of
ESCs at 24 h post-labeling, suggesting that the QDs may
have degraded.
Here, we used fluorescence spectrometer and ICP-MS
to investigate the chemical fate of CdTe/ZnS aqQDs that
had been stored in a buffer (pH 7.4) for 3 days (Table 1).
The experimental data indicated that the maximal emis-
sion was not altered. The concentrations of Cd, Te and
Zn ions released from the CdTe/ZnS QDs gradually in-
creased over time, but were extremely low, and the ra-
tios of Cd:Te and Zn:Cd did not vary significantly. This
suggests that the size and composition of CdTe/ZnSaqQDs stored in buffer did not differ significantly from
those kept in situ [22,23]. On the other hand, the
fluorescent intensity was reduced after a 6 h incubation
in a pH 7.4 buffer solution. This suggests that the
nanocrystals of CdTe/ZnS aqQDs formed surface de-
fects in a pH 7.4 environment.
Next, the Cd and Te concentrations in the blood were
measured using ICP-MS, the Cd:Te ratios were calculated,
and Cd and Te blood kinetic analyses were conducted. As
described in Tables 2 and 3, we observed differences in
the Cd:Te ratios and Cd and Te blood kinetic parameters,
suggesting that CdTe/ZnS aqQDs break down in the
blood. If CdTe/ZnS aqQDs are chemically stable in the
blood, steady or unchanged Cd:Te ratios in the blood over
time would result. Furthermore, the blood kinetic parame-
ters, CL and t1/2β of Cd and Te would be similar. As
shown in Tables 1 and 2, the relative fluorescent intensity
of QDs in pH 7.4 buffer solution was reduced rapidly after
6 h. The Cd:Te ratios also varied significantly after 6 h in
the blood. These findings indicate that the stability of
CdTe/ZnS aqQDs in the blood of the mice is comparable
to the stability in buffer solutions (pH 7.4) [13]. QDs
exhibited minimal, nonspecific binding to the cellular
components of mice blood [11].
Lastly, we examined the uptake of CdTe/ZnS aqQDs
in various organs after leaving the bloodstream using
ICP-MS. Contrary to their relatively transient fate in the
blood, Cd and Te are preferentially distributed into or-
gans and tissues (Figure 3A and B). When the specific
tissue concentrations of Cd and Te were examined, Cd
was observed to mainly accumulate in the liver and kid-
neys, which was in agreement with previous reports
[13-15,25]. Unlike Cd, the kidneys appeared to be the
major target organ for Te deposits. No significant changes
in Te accumulation were observed in the heart, liver,
spleen and lungs. On the other hand, we found that the
Cd:Te ratios in various organs over time differed. Spe-
cially, at 1 h post-injection, significant changes in Cd:Te
ratios were observed in the liver and kidneys. These
findings further indicated that CdTe/ZnS aqQDs de-
graded in specific organs, especially in the liver and kid-
neys [26], and implied that the chemical stability of
CdTe/ZnS aqQDs in vitro can not mimic the biological
responses or consequences that occur in vivo. As shown
in Table 1, CdTe/ZnS aqQDs are stable (the maximal
emission and relative fluorescence intensity of CdTe/
ZnS aqQDs were not altered) after a 1 h incubation in
pH 7.4 buffer solutions.
Metallothionein (MT) is a protein that is inducible by
various metallic elements, especially in the liver and kid-
neys. Cd is a potent inducer of MT, and Cd-MT is stable
and stored. MT-bound Cd complexes are believed to be
responsible for the long biological half-life of Cd in the
body [27,28]. It was previously demonstrated that only
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study, over a period of 28 d, we found that 42.94 and
42.60 ng/g Cd remained in the liver and kidneys,
suggesting that either significant disintegration of
CdTe/ZnS aqQDs had occurred, or that Cd had been
released in the liver and kidneys and had transferred Cd
as a Cd-MT complex during this time period. In the kid-
neys, a trend of increasing tissue concentrations was
observed at 28 d (Figure 3A). The reabsorption of Cd
indicates that renal elimination of Cd is more difficult
[29]. The half-life of Cd in the kidneys appears to be
very long. In the present study, very little Cd was dis-
tributed in the brain. The brain is a challenging organ
for drug delivery because the blood brain barrier (BBB)
functions as a gatekeeper guarding the body from ex-
ogenous substances. Small QDs may be transferred
through a space of 20 nm that separates the capillary
endothelium from the astrocytes, or QDs may interact
with the receptors located at the BBB [30].
How the stable covalent bonds of QDs were broken
biologically in the tissue remains unknown and requires
further investigation. If the dissociation of Cd from QDs
is closely associated with the toxicity of QDs in the tis-
sues, knowing how to actually define the stability of QDs
in vivo may inspire the development of new measures to
inhibit or lessen such degradation, allowing QDs to re-
main in use medically, but in a much safer manner.
Conclusions
The chemical fate of QDs in vivo is of great import-
ance. The degradation of QDs, and consequent release
of free Cd, can contribute to the overall toxicity of
QDs. While QDs in biological systems have been
traced using either fluorescent imaging methods or Cd
tracking (ICP-MS) analyses, none of these analytical
techniques or methods was actually able to define the
chemical fate of QDs in vivo. By measuring blood ki-
netic parameters, the biodistributions of Cd and Te in
CdTe/ZnS aqQDs in mice, and the Cd:Te ratios in
tissues, we clearly demonstrated that QDs are not as
stable or biologically inert as they were once widely
believed to be. In vitro, QDs are chemically stable and
do not elicit the same biological responses or conse-
quences as they do in vivo. Therefore, measuring Cd
using ICP-AES or ICP-MS in order to quantify QDs in
the plasma, organs, and excretion samples may not be
accurate. New approaches to studying the fate of QDs
in vivo should be considered. In summary, we believe
that, although the present study was a relatively simple
study, it provided very important information relative
to the chemical fate and biological safety of QDs. We
hope that our findings will inspire the manufacture of
a new generation of QDs that are just as effective, but
are also safer.Materials and methods
Characteristics of CdTe/ZnS aqQDs
The CdTe/ZnS aqQDs used in our experiments were
prepared by Zhejiang University. The CdTe/ZnS aqQDs
had a CdTe core and a ZnS shell. Thioglycolic acid (TGA)
was used as a stabilizer. The molar ratio of Cd2+:HTe-:
TGA was fixed at 3:1:3 (Cd:Te = 3:1), Zn2+:Cd2+ was fixed
at 1:1 (Zn:Cd = 1:1). Glutathione (GSH) was used as both
a capping reagent and a sulfur source for the in situ
growth of the ZnS shell on the CdTe core of the QDs.
The pH value of the latter solution was fixed at 8.3. Prior
to use in our experiments, the CdTe/ZnS aqQDs stock so-
lutions were centrifuged at 650 × g for 15 min at room
temperature to remove large aggregates. The supernatants
were then dialyzed for 4 h across a 10 kDa cellulose mem-
brane (Sigma) against a 0.1% solution of thioglycolate
(sodium salt, Sigma) at pH 8.3 to remove any free Cd,
Te, Zn or other small molecules from the solutions
[31-33]. The stock solutions were then further dialysed for
2 h against distilled water (pH 8.3) to remove unbound
thioglycolate. The size distribution and surface charac-
teristics of the CdTe/ZnS aqQDs were analyzed using
AFM (Nano Scope 3D, Veeco, USA). Meanwhile, their
fluorescence spectra, peak wavelengths and fluorescence
intensity were measured using a fluorescence spectrom-
eter (RF-5301, Shimadzu, Japan). The concentrations of
Cd, Te and Zn in the stock solution were determined as
described below. Prior to injecting the mice, the CdTe/
ZnS aqQDs solutions were freshly dissolved in a normal
sodium medium containing PBS (pH 7.4) and sonicated
for 5 min in order to allow the CdTe/ZnS aqQDs parti-
cles to disperse evenly throughout the solution. The
final concentrations of the solutions were adjusted to
50 nmol/ml (calculated based on the molar mass of Cd).
Stability of CdTe/ZnS aqQDs in vitro
The PLQYs of CdTe/ZnS aqQDs in situ (pH 8.3) were
measured relative to Rhodamine 6G (Fluka) in ethanol
over a period of 80 days. In addition, we mimicked the pH
of blood (pH 7.4) in order to investigate the stability of
CdTe/ZnS aqQDs in vitro. CdTe/ZnS aqQDs (50 nmol/
ml) were dissolved in PBS solutions (pH 7.4) at 37°C and
added to 10 kDa dialysis tubes. The dialysis tubes were
placed in polypropylene beakers containing PBS. The
fluorescence spectra and relative fluorescent intensities of
the solutions in the tubes were measured using a fluores-
cence spectrometer 15 min, 30 min, 1 h, 6 h, 24 h, 2 d and
3 d after the tubes were placed in the beakers. The con-
centrations of Cd, Te and Zn in the filtrate were quantita-
tively measured using ICP-MS (7500ce, Agilent, USA).
The lowest standard (1 ng/ml) on the calibration curve at
which the analyte peak was identifiable and reproducible
with a precision of less than 20% was designated as the
lower limit of quantification. Calibration plots for Cd, Te
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solutions (1, 5, 10, 50, and 100 ng/ml in 2% HNO3, flow
rate: 1.0 ml/min) into the ICP-MS. Both Cd:Te ratio and
Zn:Cd ratio were then calculated based on the concentra-
tions of Cd, Te and Zn. The results for the PBS solutions
were compared to those for the initial CdTe/ZnS aqQDs.
Animals
Healthy male ICR mice (six weeks old) were purchased
from Beijing (Military Medical Science Academy of the
People’s Liberation Army). The mice were housed in a
ventilated, temperature-controlled, and standardized ste-
rile animal room with a 12 h day/night cycle at the China
Capital Medical University. The mice were allowed to ac-
climate to the animal room for 7 days prior to experimen-
tation. All procedures used in this study were performed
in accordance with animal welfare protocols that had been
approved by the Capital Medical University Animal Care
and Use Committee (approval number 2011-X-072).
Animal treatment
Mice weighing between 23.8 and 26.8 g were adminis-
tered the CdTe/ZnS aqQD solution via tail vein injection
at a dose of 0.2 μmol CdTe/ZnS aqQDs/kg of body
weight [13] (which was calculated based on the molar
mass of Cd). The mice in the control group were injected
with an equivalent volume of normal saline. Preliminary
observations of food intake, fur, behavior, mental status,
urine and faeces were conducted daily for each mouse. At
predetermined time points (1 min, 15 min, 30 min, 1 h,
6 h, 12 h, 24 h, 3 d, 7 d, 14 d, and 28 d), six mice from
each exposed group were anesthetized using isoflurane.
Retro-orbital blood was collected into Eppendorf tubes
containing heparin (10 μl, 500 IU/ml) and stored at 4°C
for further analysis. The mice were then euthanized by
cervical dislocation, and the hearts, livers, spleens, lungs,
kidneys, and brains were collected. Meanwhile, the control
mice were also killed, at predetermined time (7 d, 14 d,
and 28 d), strictly according to the procedure through
which the exposed mice were treated. The body weight of
each mouse and the weights of all organs were recorded.
Tissues samples were stored at −80°C.
Measurement of Cd and Te concentrations using ICP-MS
Blood (200 μl) and portions of the excised organs (0.1 −
0.5 g), which had been rinsed with sterile saline to remove
any remaining traces of blood, were soaked in nitric acid
(HNO3, 67%, MOS grade) in a glass beaker overnight.
In addition, a 50 ng/ml indium (115In) salt solution was
added as an internal standard to ensure the accuracy
and precision of the technique. To digest the samples,
the beakers were heated to 110–120°C in a mixture of
HNO3 and H2O2 (volume ratio 4:1) until the solution
was colorless and clear. H2O2 was used to eliminatenitrogen oxide vapors. Lastly, the solution volume was
fixed at 2 ml using diluted nitric acid (2%) and the so-
lution was passed through a 0.45 μm pore poly-
vinylidene fluoride membrane syringe filter. The
concentrations of Cd and Te in the filtrates were quan-
titatively measured using ICP-MS. The mean values of
Cd and Te in the control mice were deducted as the
background for the blood and organs (heart, liver,
spleen, lungs, kidneys, and brain) (Additional file 2:
Table S2). Additionally, the Cd:Te ratios in administra-
tive mice were calculated. The in vivo results were
compared to that of initial CdTe/ZnS aqQDs.
Kinetic analyses and statistical analyses
Kinetic analyses of Cd and Te in the blood were carried
out using Drug and Statistics (DAS) software version 2.0
(Mathematical Pharmacology Professional Committee of
China, Shanghai, China). Kinetic parameters were calcu-
lated, including the apparent volume of distribution
(Vd), AUC, CL, as well as the distribution half-life
(t1/2α) and t1/2β. The kinetic parameters were estimated
separately for each animal. The data are expressed as
the mean ± SD. t-testing of the data was performed
using the Statistical Package for Social Sciences version
13.0 (SPSS13.0). p values < 0.01 or 0.05 were considered
to be significant.
Additional files
Additional file 1: Table S1. Tissue weights of the control and CdTe/
ZnS aqQDs exposure groups. ICR mice were injected via tail vein with
CdTe/ZnS aqQDs (0.2 μmol/kg). At predetermined time points (7 d, 14 d,
and 28 d) after dosing, the body weight of each mouse and the weights
of all organs were recorded. Compared with respective controls, the
tissue weights in mice exposed to CdTe/ZnS aqQDs did not vary
significantly (P >0.05).
Additional file 2: Table S2. Concentrations of Cd and Te of control
mice. The detection limits for Cd and Te are 0.1 ppb (ng/ml).
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